NC
ITCI

Nexthera Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Nexthera Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$1.86M Buy
+143,665
New +$1.84M 1.55% 17

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Nexthera Capital's ITCI Position: Q2 2019 in Review

Nexthera Capital opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q2 2019: 143,665 shares worth $1.86M. The stake represents 1.55% of the portfolio and ranks #17 among its holdings.

126 funds tracked by Wall St. Rank hold ITCI as of Q2 2019.

  • Nexthera Capital held 143,665 shares of Intra-Cellular Therapies Inc. worth $1.86M as of Q2 2019.
  • Intra-Cellular Therapies Inc. was a new Nexthera Capital position in Q2 2019.
  • Intra-Cellular Therapies Inc. made up 1.55% of Nexthera Capital's portfolio in Q2 2019, its #17 holding.
  • 126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.